

Ciaran M Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2772951/publications.pdf>

Version: 2024-02-01

56
papers

4,436
citations

159525

30
h-index

161767

54
g-index

63
all docs

63
docs citations

63
times ranked

6028
citing authors

#	ARTICLE	IF	CITATIONS
1	A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. <i>Nature Medicine</i> , 2018, 24, 1216-1224.	15.2	573
2	CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery. <i>Chemical Reviews</i> , 2017, 117, 9874-9906.	23.0	418
3	CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. <i>Blood</i> , 2017, 130, 285-296.	0.6	326
4	COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e214.	2.3	315
5	<i>Streptococcus thermophilus</i> CRISPR-Cas9 Systems Enable Specific Editing of the Human Genome. <i>Molecular Therapy</i> , 2016, 24, 636-644.	3.7	204
6	The <i>Neisseria meningitidis</i> CRISPR-Cas9 System Enables Specific Genome Editing in Mammalian Cells. <i>Molecular Therapy</i> , 2016, 24, 645-654.	3.7	190
7	Gene correction for SCID-X1 in long-term hematopoietic stem cells. <i>Nature Communications</i> , 2019, 10, 1634.	5.8	140
8	AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9. <i>Molecular Therapy</i> , 2020, 28, 1432-1441.	3.7	140
9	Engineered materials for in vivo delivery of genome-editing machinery. <i>Nature Reviews Materials</i> , 2019, 4, 726-737.	23.3	139
10	Highly efficient editing of the β -globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease. <i>Nucleic Acids Research</i> , 2019, 47, 7955-7972.	6.5	110
11	Efficient CRISPR/Cas9-Mediated Genome Editing Using a Chimeric Single-Guide RNA Molecule. <i>Frontiers in Plant Science</i> , 2017, 8, 1441.	1.7	107
12	Spatial control of in vivo CRISPR-Cas9 genome editing via nanomagnets. <i>Nature Biomedical Engineering</i> , 2019, 3, 126-136.	11.6	107
13	Nuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off-target Effects in Genome Editing. <i>Molecular Therapy</i> , 2016, 24, 475-487.	3.7	100
14	Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements. <i>Molecular Therapy</i> , 2019, 27, 137-150.	3.7	97
15	High-Efficiency, Selection-free Gene Repair in Airway Stem Cells from Cystic Fibrosis Patients Rescues CFTR Function in Differentiated Epithelia. <i>Cell Stem Cell</i> , 2020, 26, 161-171.e4.	5.2	97
16	A Self-Deleting AAV-CRISPR System for In Vivo Genome Editing. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 12, 111-122.	1.8	93
17	Therapeutically relevant engraftment of a CRISPR-Cas9-edited HSC-enriched population with HbF reactivation in nonhuman primates. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	88
18	Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I. <i>Nature Communications</i> , 2019, 10, 4045.	5.8	88

#	ARTICLE	IF	CITATIONS
19	A Burden of Rare Variants Associated with Extremes of Gene Expression in Human Peripheral Blood. <i>American Journal of Human Genetics</i> , 2016, 98, 299-309.	2.6	84
20	CRISPR-based gene editing enables <i>FOXP3</i> gene repair in IPEX patient cells. <i>Science Advances</i> , 2020, 6, eaaz0571.	4.7	84
21	Development of β -globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	82
22	Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease. <i>Scientific Reports</i> , 2017, 7, 44624.	1.6	76
23	Correction of the Δ F508 Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Gene by Zinc-Finger Nuclease Homology-Directed Repair. <i>BioResearch Open Access</i> , 2012, 1, 99-108.	2.6	74
24	In Vivo <i>Ryr2</i> Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation Research</i> , 2018, 123, 953-963.	2.0	63
25	Somatic Editing of <i>Ldlr</i> With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1997-2006.	1.1	63
26	TNF- α synergises with IFN- β to induce caspase-8/JAK1/2-STAT1-dependent death of intestinal epithelial cells. <i>Cell Death and Disease</i> , 2021, 12, 864.	2.7	54
27	Tools for experimental and computational analyses of off-target editing by programmable nucleases. <i>Nature Protocols</i> , 2021, 16, 10-26.	5.5	52
28	Genome editing of donor-derived T-cells to generate allogeneic chimeric antigen receptor-modified T cells: Optimizing β T cell-depleted haploidentical hematopoietic stem cell transplantation. <i>Haematologica</i> , 2021, 106, 847-858.	1.7	46
29	Efficient Δ Cas9 Synthetic Endonuclease with Improved Specificity for Precise Genome Engineering. <i>PLoS ONE</i> , 2015, 10, e0133373.	1.1	46
30	Genome editing for inborn errors of metabolism: advancing towards the clinic. <i>BMC Medicine</i> , 2017, 15, 43.	2.3	42
31	Metabolic engineering generates a transgene-free safety switch for cell therapy. <i>Nature Biotechnology</i> , 2020, 38, 1441-1450.	9.4	39
32	Collagen-rich airway smooth muscle cells are a metastatic niche for tumor colonization in the lung. <i>Nature Communications</i> , 2019, 10, 2131.	5.8	27
33	Analysis of gene repair tracts from Cas9/gRNA double-stranded breaks in the human CFTR gene. <i>Scientific Reports</i> , 2016, 6, 32230.	1.6	26
34	Targeted replacement of full-length CFTR in human airway stem cells by CRISPR-Cas9 for pan-mutation correction in the endogenous locus. <i>Molecular Therapy</i> , 2022, 30, 223-237.	3.7	24
35	The TRACE-Seq method tracks recombination alleles and identifies clonal reconstitution dynamics of gene targeted human hematopoietic stem cells. <i>Nature Communications</i> , 2021, 12, 472.	5.8	23
36	Controlled delivery of β -globin-targeting TALENs and CRISPR/Cas9 into mammalian cells for genome editing using microinjection. <i>Scientific Reports</i> , 2015, 5, 16031.	1.6	20

#	ARTICLE	IF	CITATIONS
37	Examination of CRISPR/Cas9 design tools and the effect of target site accessibility on Cas9 activity. <i>Experimental Physiology</i> , 2018, 103, 456-460.	0.9	20
38	High-Throughput Imaging of CRISPR- and Recombinant Adeno-Associated Virus-Induced DNA Damage Response in Human Hematopoietic Stem and Progenitor Cells. <i>CRISPR Journal</i> , 2022, 5, 80-94.	1.4	16
39	Treating hemoglobinopathies using gene-correction approaches: promises and challenges. <i>Human Genetics</i> , 2016, 135, 993-1010.	1.8	13
40	Therapeutic Crispr/Cas9 Genome Editing for Treating Sickle Cell Disease. <i>Blood</i> , 2016, 128, 4703-4703.	0.6	13
41	Design and Validation of CRISPR/Cas9 Systems for Targeted Gene Modification in Induced Pluripotent Stem Cells. <i>Methods in Molecular Biology</i> , 2017, 1498, 3-21.	0.4	10
42	InÂvivo genome editing at the albumin locus to treat methylmalonic acidemia. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 23, 619-632.	1.8	10
43	Fine-mapping within eQTL credible intervals by expression CROP-seq. <i>Biology Methods and Protocols</i> , 2020, 5, bpaa008.	1.0	8
44	Pitfalls in Single Clone CRISPR-Cas9 Mutagenesis to Fine-Map Regulatory Intervals. <i>Genes</i> , 2020, 11, 504.	1.0	6
45	Site-Specific Post-translational Surface Modification of Adeno-Associated Virus Vectors Using Leucine Zippers. <i>ACS Synthetic Biology</i> , 2020, 9, 461-467.	1.9	6
46	331. Development of <i>Neisseria meningitidis</i> CRISPR/Cas9 Systems for Efficient and Specific Genome Editing. <i>Molecular Therapy</i> , 2015, 23, S132-S133.	3.7	4
47	Gene Editing with Crispr-Cas9 for Treating Beta-Hemoglobinopathies. <i>Blood</i> , 2015, 126, 3376-3376.	0.6	4
48	Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and Î²-Thalassemia. <i>Blood</i> , 2016, 128, 4708-4708.	0.6	2
49	131. Chromatin-Dependent Loci Accessibility Affects CRISPR-Cas9 Targeting Efficiency. <i>Molecular Therapy</i> , 2016, 24, S54.	3.7	1
50	Engineered Human Umbilical Cord Derived Erythroid Progenitor Cells (HUDEP2) with Sickle or Î²-Thalassemia Mutation: An in-Vitro System for Testing Pharmacological Induction of Fetal Hemoglobin. <i>Blood</i> , 2018, 132, 3478-3478.	0.6	1
51	Highly Efficient Editing of the Beta-Globin Gene in Patient Derived Hematopoietic Stem and Progenitor Cells to Treat Sickle Cell Disease. <i>Blood</i> , 2018, 132, 2192-2192.	0.6	1
52	Identification and Validation of CRISPR/Cas9 Off-Target Activity in Hematopoietic Stem and Progenitor Cells. <i>Methods in Molecular Biology</i> , 2022, 2429, 281-306.	0.4	1
53	Abstract O32: Somatic Editing of Ldlr with AAV-CRISPR for Atherosclerosis Studies. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, .	1.1	0
54	Sickle Human Umbilical Cord Derived Erythroid Progenitor Cells (S-HUDEP2): An Ideal in-Vitro System for Screening Anti-Sickling Compounds for Sickle Cell Disease. <i>Blood</i> , 2018, 132, 3675-3675.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Persistence of CRISPR/Cas9-Edited Hematopoietic Stem and Progenitor Cells and Reactivation of Fetal Hemoglobin in Nonhuman Primates. <i>Blood</i> , 2018, 132, 806-806.	0.6	0
56	Modulation of inhibitory signals in CAR T cells leads to improved activity against glioblastoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3031-3031.	0.8	0